Lemmon/Prographarm
Executive Summary
ANDA for diltiazem extended-release is held by Prographarm USA, Ltd., a wholly-owned subsidiary of Lemmon ("The Pink Sheet" Dec. 6, T&G-9). "There is no equity relationship between, Prographarm, the French drug delivery company who collaborated with Teva Pharmaceutical Industries, Ltd. and Lemmon Company in the development of diltiazem ER capsules, and Prographarm USA, Ltd., the sponsor of the ANDA," Lemmon explains.